Indications
Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.
Composition
- Active substance
- odronextamab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ordspono
- Active substance
- odronextamab
- ATC code
- Not yet assigned
- Group
- Nervous system
- Therapeutic area
- Lymphoma, Follicular
- Marketing authorisation holder
- Regeneron Ireland Designated Activity Company (DAC)